Guiying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guiying Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Baoheng Xing
Department of Maternity, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province, 061001, People’s Republic of China
1 shared publication - Dongliang Shi
Department of Oncology, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province, 061001, People’s Republic of China
1 shared publication - Jingyan Yang
Department of Anesthesiology, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province, 061001, People’s Republic of China
1 shared publication - Liang Wang
Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute Of Radiation Medicine, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publication - Yulei Zhao
Department of Hematology, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province, 061001, People’s Republic of China
1 shared publication - Zhijing Wang
Department of Cerebral Surgery, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province, 061001, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 369
Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer
The potential of secretory leukocyte protease inhibitor (SLPI) as a biomarker for colorectal cancer was studied. A prospective, randomized, controlled, clinical trial was conducted in 2013 and 2014 to confirm whether the expression of SLPI correlates with prognosis and metastasis in colorectal cancer patients. Immunohistochemistry was used to detect SLPI expression in colorectal cancer. The expression of SLPI was scored by two pathologists independently. Statistical analysis of the data was performed using a Χ2 test to investigate the influence of SLPI on the pathologic characteristics of colorectal cancer. Compared with normal tissue, SLPI was overexpressed in colorectal cancer tissue. Overexpression of SLPI correlated with different grades (moderate or good differentiation: 2.7% low expression versus 97.3% high expression, low differentiation: 41.7% low expression versus 58.3% high expression), TNM stage (I or II: 4.2% low expression versus 95.8% high expression; III or IV: 19.7% low expression versus 80.3% high expression), lymphatic metastasis (18.6% low expression versus 81.4% high expression) and distal metastasis (86.5% low expression versus 13.5% high expression), but not with patient age or sex (P = 0.613, P = 0.871). Upregulated SLPI correlates with aggressive pathologic characteristics of colorectal cancer; SLPI could be used as an indicator of progression and metastasis in patients with colorectal cancer.
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 369
Open AccessExpression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer
The potential of secretory leukocyte protease inhibitor (SLPI) as a biomarker for colorectal cancer was studied. A prospective, randomized, controlled, clinical trial was conducted in 2013 and 2014 to confirm whether the expression of SLPI correlates with prognosis and metastasis in colorectal cancer patients. Immunohistochemistry was used to detect SLPI expression in colorectal cancer. The expression of SLPI was scored by two pathologists independently. Statistical analysis of the data was performed using a Χ2 test to investigate the influence of SLPI on the pathologic characteristics of colorectal cancer. Compared with normal tissue, SLPI was overexpressed in colorectal cancer tissue. Overexpression of SLPI correlated with different grades (moderate or good differentiation: 2.7% low expression versus 97.3% high expression, low differentiation: 41.7% low expression versus 58.3% high expression), TNM stage (I or II: 4.2% low expression versus 95.8% high expression; III or IV: 19.7% low expression versus 80.3% high expression), lymphatic metastasis (18.6% low expression versus 81.4% high expression) and distal metastasis (86.5% low expression versus 13.5% high expression), but not with patient age or sex (P = 0.613, P = 0.871). Upregulated SLPI correlates with aggressive pathologic characteristics of colorectal cancer; SLPI could be used as an indicator of progression and metastasis in patients with colorectal cancer.